{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:32:37Z","timestamp":1790775157998,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The impact of moderate drinking on the risk of liver fibrosis in non-alcoholic fatty liver disease (NAFLD) remains controversial worldwide. Notably, China, with the fastest-growing incidence of NAFLD and the highest number of alcohol-attributable deaths globally, has relatively few studies addressing this issue. This study aimed to explore the association between alcohol consumption and liver fibrosis in Chinese men with metabolic dysfunction-associated steatotic liver disease (MASLD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We recruited 4,683 male employees diagnosed with MASLD from southwest China, including 4,287 with pure MASLD and 396 with metabolic and alcohol-related liver disease (MetALD) who consumed increased alcohol (30-60 g\/d). Advanced fibrosis was defined as a fibrosis-4 index (FIB-4) \u2265 2.67, and FIB-4 \u2265 1.30 indicated an intermediate\/high probability of hepatic fibrosis. Logistic regression models were used to assess the association between alcohol consumption and hepatic fibrosis, and analyze the modification effect of body mass index (BMI) and waist-to-hip ratio (WHR) on the association. Propensity score matching method was used to test the robustness of the regression results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with non-drinkers, both moderate (OR = 3.02, 95% CI: 1.16-10.31) and increased alcohol consumption (OR = 4.64, 95% CI: 1.60-16.82) were significantly associated with an increased risk of advanced fibrosis in males with MASLD. Additionally, moderate (OR = 1.33, 95% CI: 1.07-1.66) and increased drinking (OR = 1.74, 95% CI: 1.28-2.34) were associated with intermediate\/high probability of hepatic fibrosis, with similar results from logistic regression analysis in propensity score-matched cases. Trend analysis revealed the risk of hepatic fibrosis increased with increasing alcohol intake (FIB-4 \u2265 1.30, <jats:italic>p<\/jats:italic> for trend &amp;lt; 0.001; FIB-4 \u2265 2.67, <jats:italic>p<\/jats:italic> for trend = 0.007). Further subgroup analysis showed that the association between moderate drinking and intermediate\/high probability of hepatic fibrosis was predominantly observed in males with BMI \u2265 23 kg\/m<jats:sup>2<\/jats:sup> (OR = 1.35, 95% CI: 1.08-1.69) and those with WHR \u2265 0.9 (OR = 1.40, 95% CI: 1.11-1.78).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In China, moderate alcohol intake may heighten the risk of hepatic fibrosis in males with MASLD who are overweight\/obese or have abdominal obesity. Moreover, males with MetALD may have a higher risk of fibrosis compared to those with pure MASLD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1572853","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:34:30Z","timestamp":1745818470000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Association between alcohol consumption and hepatic fibrosis in Chinese adult males with metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Mao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: Diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review.","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.21037\/hbsn-23-556","article-title":"The global burden of fatty liver disease: The major impact of China.","volume":"13","author":"Lou","year":"2024","journal-title":"Hepatobiliary Surg Nutr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China.","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American heart association.","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.21037\/hbsn-22-421","article-title":"An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.","volume":"12","author":"Sun","year":"2023","journal-title":"Hepatobiliary Surg Nutr."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease.","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/S0140-6736(18)32744-2","article-title":"Global alcohol exposure between 1990 and 2017 and forecasts until 2030: A modelling study.","volume":"393","author":"Manthey","year":"2019","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.3350\/cmh.2022.0393","article-title":"The effects of moderate alcohol consumption on non-alcoholic fatty liver disease.","volume":"29","author":"Oh","year":"2023","journal-title":"Clin Mol Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"744713","DOI":"10.3389\/fmed.2021.744713","article-title":"The effects of modest alcohol consumption on non-alcoholic fatty liver disease: A systematic review and meta-analysis.","volume":"8","author":"Wongtrakul","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/hep.30867","article-title":"Low levels of alcohol consumption, obesity, and development of fatty liver with and without evidence of advanced fibrosis.","volume":"71","author":"Chang","year":"2020","journal-title":"Hepatology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0003","DOI":"10.1097\/HC9.0000000000000003","article-title":"Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD.","volume":"7","author":"Blomdahl","year":"2023","journal-title":"Hepatol Commun."},{"key":"B13","year":"2018","journal-title":"Global Status Report on Alcohol and Health 2018."},{"key":"B14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/hep.32123","article-title":"Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity.","volume":"75","author":"Innes","year":"2022","journal-title":"Hepatology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/S0140-6736(18)31772-0","article-title":"Conventional and genetic evidence on alcohol and vascular disease aetiology: A prospective study of 500 000 men and women in China.","volume":"393","author":"Millwood","year":"2019","journal-title":"Lancet."},{"key":"B16","year":"2013","journal-title":"Adult Weight Determination in the Health Industry Standard of the People\u2019s Republic of China: WS\/T428\u20132013."},{"key":"B17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.je.2017.03.001","article-title":"Prevalence of abdominal obesity among Chinese adults in 2011.","volume":"27","author":"Du","year":"2017","journal-title":"J Epidemiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1751-2980.2010.00476.x","article-title":"Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166).","volume":"12","author":"Fan","year":"2011","journal-title":"J Dig Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1007\/s00125-024-06196-3","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.","volume":"67","year":"2024","journal-title":"Diabetologia."},{"key":"B20","year":"2006","journal-title":"Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO\/IDF Consultation."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.","volume":"59","year":"2016","journal-title":"Diabetologia."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1284509","DOI":"10.3389\/fnut.2024.1284509","article-title":"Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: A meta-analysis of over 40,000 participants.","volume":"11","author":"Lopez Torrez","year":"2024","journal-title":"Front Nutr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jhep.2024.05.042","article-title":"Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort.","volume":"81","author":"Oh","year":"2024","journal-title":"J Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD.","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"100596","DOI":"10.1016\/j.jhepr.2022.100596","article-title":"Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice.","volume":"5","author":"Lazarus","year":"2023","journal-title":"JHEP Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"Electronic address EEE, clinical practice guideline P, chair, representative egb, panel m. easl clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.","volume":"75","year":"2021","journal-title":"J Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3390\/jpm12122009","article-title":"Serum uric acid but not ferritin level is associated with hepatic fibrosis in lean subjects with metabolic dysfunction-associated fatty liver disease: A community-based study.","volume":"12","author":"Xie","year":"2022","journal-title":"J Pers Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with Type 2 diabetes followed in the outpatient setting: the need for systematic screening.","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/jgh.15073","article-title":"Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study.","volume":"35","author":"Chen","year":"2020","journal-title":"J Gastroenterol Hepatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1161\/HYPERTENSIONAHA.120.15220","article-title":"Nonalcoholic fatty liver disease and advanced fibrosis in US adults across blood pressure categories.","volume":"76","author":"Ciardullo","year":"2020","journal-title":"Hypertension."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1093\/eurheartj\/ehz381","article-title":"The 2018 ESC\/ESH Guidelines for the management of arterial hypertension: A German point of view.","volume":"40","author":"Emrich","year":"2019","journal-title":"Eur Heart J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3967\/bes2023.118","article-title":"Dietary guide for hyperuricemia and gout patients (WS\/T 560-2017).","volume":"36","year":"2023","journal-title":"Biomed Environ Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1022977","DOI":"10.3389\/fnut.2022.1022977","article-title":"Effects of beer, wine, and baijiu consumption on non-alcoholic fatty liver disease: Potential implications of the flavor compounds in the alcoholic beverages.","volume":"9","author":"Zhou","year":"2022","journal-title":"Front Nutr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41395-018-0133-5","article-title":"Type and pattern of alcohol consumption is associated with liver fibrosis in patients with non-alcoholic fatty liver disease.","volume":"113","author":"Mitchell","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.clnu.2012.08.022","article-title":"Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: A randomized clinical trial.","volume":"32","author":"Chiva-Blanch","year":"2013","journal-title":"Clin Nutr."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.7150\/thno.22414","article-title":"Targeting ALDH2 for therapeutic interventions in chronic pain-related myocardial ischemic susceptibility.","volume":"8","author":"Li","year":"2018","journal-title":"Theranostics."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.alcohol.2020.07.010","article-title":"Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease.","volume":"89","author":"Kashiwagi","year":"2020","journal-title":"Alcohol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/apt.13067","article-title":"The combined effects of alcohol consumption and body mass index on hepatic steatosis in a general population sample of European men and women.","volume":"41","author":"Lau","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/jgh.14770","article-title":"Genetic and lifestyle risk factors for advanced liver disease among men and women.","volume":"35","author":"Sahlman","year":"2020","journal-title":"J Gastroenterol Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1097\/HEP.0000000000000664","article-title":"Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.","volume":"79","author":"Lee","year":"2024","journal-title":"Hepatology."},{"key":"B41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12916-021-02079-1","article-title":"Alcohol drinking and risks of liver cancer and non-neoplastic chronic liver diseases in China: A 10-year prospective study of 0.5 million adults.","volume":"19","author":"Im","year":"2021","journal-title":"BMC Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/acer.14271","article-title":"Interaction between alcohol use and metabolic risk factors for liver disease: A critical review of epidemiological studies.","volume":"44","author":"Aberg","year":"2020","journal-title":"Alcohol Clin Exp Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/gast.2002.35354","article-title":"The utility of radiological imaging in nonalcoholic fatty liver disease.","volume":"123","author":"Saadeh","year":"2002","journal-title":"Gastroenterology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"101547","DOI":"10.1016\/j.eclinm.2022.101547","article-title":"Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.","volume":"51","author":"Cao","year":"2022","journal-title":"EClinicalMedicine."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1572853\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:34:31Z","timestamp":1745818471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1572853\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":45,"alternative-id":["10.3389\/fmed.2025.1572853"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1572853","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"article-number":"1572853"}}